Current Report Filing (8-k)
August 06 2019 - 8:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2019 (August 6, 2019)
ALLERGAN PLC
(Exact Name
of Registrant as Specified in Charter)
|
|
|
|
|
Ireland
|
|
001-36867
|
|
98-1114402
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Clonshaugh Business and Technology Park
Coolock, Dublin, D17 E400, Ireland
(Address of Principal Executive Offices)
(862)
261-7000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c)
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to
Section 12(b) of the Exchange Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Ordinary Share, par value $0.0001 per share
|
|
AGN
|
|
New York Stock Exchange
|
Floating rate notes due 2020
|
|
AGN20A
|
|
New York Stock Exchange
|
0.500% notes due 2021
|
|
AGN21
|
|
New York Stock Exchange
|
1.500% notes due 2023
|
|
AGN23A
|
|
New York Stock Exchange
|
1.250% notes due 2024
|
|
AGN24A
|
|
New York Stock Exchange
|
2.625% notes due 2028
|
|
AGN28
|
|
New York Stock Exchange
|
2.125% notes due 2029
|
|
AGN29
|
|
New York Stock Exchange
|
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2019, Allergan plc (the Company) posted an investor FAQ entitled Second Quarter 2019 Financial Results Frequently
Asked Questions (the Investor FAQ) to the investor relations section of its website. The Investor FAQ is related to the Companys earnings release for the quarter ended June 30, 2019. A copy of the Investor FAQ is
attached hereto as an Exhibit 99.1.
The information in this Item 2.02 is being furnished to the U.S. Securities and Exchange Commission and shall not be
deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, and such information shall not be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: August 6, 2019
|
|
|
|
Allergan plc
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A. Robert D. Bailey
|
|
|
|
|
|
|
A. Robert D. Bailey
|
|
|
|
|
|
|
EVP and Chief Legal Officer and Corporate Secretary
|
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024